| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8715069 | Journal of the American Academy of Dermatology | 2018 | 51 Pages |
Abstract
Fezakinumab was well-tolerated, with sustained clinical improvements after last drug dosing.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Emma MD, PhD, Patrick M. MD, Avidan U. PhD, Saakshi MD, Ana B. PhD, Kunal BA, Giselle K. BS, Danielle Baum, Patricia Gilleaudeau, Mary Sullivan-Whalen, Sharon MD, Shelbi MD, Xuan BA, Judilyn MD, Yeriel BS, Sandra PhD, Claudia MD, James G. MD, PhD,